• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

After February market crash, ProQR will lay off 30% of its workforce and try pushing eye...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Apr 13, 2022 at 11:02: AM
via A pivotal trial flop in February caused ProQR to lose nearly two-thirds of its stock value and that means the transatlantic company will officially join the dozens of biotechs and pharmas to lay off employees in the past few months.

article source
 




Top Bottom
Back
Quote